ZYME

Zymeworks BC Inc

29.07

Nov 12 • 5:42 AM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

Nov 11, 6:32 PMNo clear catalyst identified; Zymeworks falls 7.6% despite rising biotech sector and Citi target hike

Peers: LGND XNCR INVA JAZZ RPRX MGNX ANAB GMAB BNTX STRO

| Held by: VTI IWM IBB IWO DFAS VTWO FESM DFMC CANC VHT

Scroll to Statements

Index	RUT
Market Cap	2.02B
Enterprise Value	2.57B
Income	43.31M
Sales	265.97M
Book/sh	3.60
Cash/sh	1.44
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	264
IPO	Apr 28, 2017

P/E	55.67
Forward P/E	42.51
PEG	-
P/S	7.60
P/B	8.07
P/C	20.13
P/FCF	-
EV/EBITDA	48.37
EV/Sales	9.67
Quick Ratio	3.30
Current Ratio	3.30
Debt/Eq	2.52
LT Debt/Eq	2.47
Option/Short	Yes / Yes

EPS (ttm)	0.52
EPS next Y	0.68
EPS next Q	0.30
EPS this Y	206.06%
EPS next Y	-40.30%
EPS next 5Y	-
EPS past 3/5Y	- 21.35%
Sales past 3/5Y	-36.43% 22.16%
EPS Y/Y TTM	179.45%
Sales Y/Y TTM	97.78%
EPS Q/Q	980.56%
Sales Q/Q	828.73%
Earnings	Nov 09 AMC
EPS/Sales Surpr.	0.39% 12.78%

Insider Own	3.65%
Insider Trans	-0.54%
Inst Own	98.57%
Inst Trans	-4.16%
ROA	5.50%
ROE	14.98%
ROIC	4.83%
Gross Margin	96.61%
Oper. Margin	16.60%
Profit Margin	16.28%
SMA20	1.20%
SMA50	5.92%
SMA200	13.93%
Trades

Shs Outstand	71.18M
Shs Float	67.02M
Short Float	8.83%
Short Ratio	5.65
Short Interest	5.91M
52W High	31.97 -9.07%
52W Low	18.20 59.73%
Volatility	6.37% 4.42%
ATR (14)	1.28
RSI (14)	52.76
Beta	1.30
Rel Volume	0.00
Avg Volume	1.05M
Volume	2

Perf Week	1.17%
Perf Month	17.36%
Perf Quarter	15.72%
Perf Half Y	21.33%
Perf YTD	10.41%
Perf Year	50.08%
Perf 3Y	298.77%
Perf 5Y	44.27%
Perf 10Y	-
Recom	1.00
Target Price	42.79
Prev Close	29.07
Price	29.07
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$42.79

Implied Upside

+47.2%

Analysts12incl. previous ratings

Rating Distribution11 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Sep 29, 2026	Initiated	TTD Cowen	Buy	$34	+17.0%
Sep 17, 2026	Initiated	WWolfe Research	Outperform
Aug 26, 2026	Reiterated	HH.C. Wainwright	Buy	$51 → $55	+89.2%
Jun 09, 2026	Resumed	TTruist	Buy	$28	-3.7%
Dec 12, 2025	Upgrade	WWells Fargo	Equal Weight → Overweight	$33	+13.5%
Dec 03, 2025	Initiated	CCitizens JMP	Mkt Outperform	$32	+10.1%
Oct 24, 2025	Resumed	WWells Fargo	Equal Weight	$15	-48.4%
Oct 14, 2025	Upgrade	HH.C. Wainwright	Neutral → Buy	$26	-10.6%
Oct 10, 2025	Initiated	RB. Riley Securities	Buy	$30	+3.2%
May 20, 2025	Initiated	TTD Cowen	Buy
Dec 16, 2024	Upgrade	JJP Morgan	Neutral → Overweight	$18	-38.1%
Nov 07, 2024	Upgrade	LLeerink Partners	Market Perform → Outperform	$10 → $25	-14.0%
Nov 01, 2024	Downgrade	WWells Fargo	Overweight → Equal Weight	$12	-58.7%
Mar 21, 2023	Resumed	WWells Fargo	Overweight	$12	-58.7%
Jan 04, 2023	Reiterated	HH.C. Wainwright	Neutral	$10 → $8	-72.5%
Dec 20, 2022	Upgrade	JJefferies	Hold → Buy	$7.70 → $11	-62.2%
Nov 01, 2022	Downgrade	HH.C. Wainwright	Buy → Neutral	$40 → $8	-72.5%
Oct 21, 2022	Downgrade	SSVB Leerink	Outperform → Mkt Perform	$8	-72.5%
Oct 04, 2022	Resumed	WWells Fargo	Overweight	$45 → $9	-69.0%
May 05, 2022	Upgrade	GGuggenheim	Neutral → Buy	$14	-51.8%

Nov-09-26 04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results (GlobeNewswire)
Nov-02-26 11:18PM	Zymeworks Faces A One-Quarter Revenue Windfall Test As Street Sits Above Its Guidance (Earnings Whispers)
Oct-27-26 07:00AM	Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors (Business Wire)
Oct-26-26 09:59AM	Another autoimmune CAR-T death; Treasury zeroes in on China deals (BioPharma Dive)
Oct-24-26 02:30AM	Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 (GlobeNewswire)
08:01PM	Loading…
Oct-23-26 08:01PM	Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week (Stocktwits)
09:25AM	Zymeworks stock surges on $813M Roche licensing deal (Investing.com)
06:00AM	Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3 (GlobeNewswire)
Oct-19-26 06:00AM	Zymeworks Appoints Suzanne Monahan as Senior Vice President, Commercial and General Manager, Theravance Biopharma (GlobeNewswire)
Oct-15-26 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences and Date of Third Quarter 2026 Financial Results (GlobeNewswire)
Sep-28-26 06:00AM	Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition (GlobeNewswire)
Sep-23-26 04:01PM	Zymeworks Completes Acquisition of Theravance Biopharma (GlobeNewswire)
Aug-26-26 01:59PM	SJM, ZYME Stocks Hit 52-Week High Whats Driving The Surge Today? (Stocktwits) +6.68%
Aug-25-26 01:21PM	New Jazz cancer drug approval could drive blockbuster sales (BioPharma Dive)
12:26PM	JAZZ, ONC, ZYME Stocks In Focus After FDA Approves Gastroesophageal Cancer Therapy (Stocktwits)
10:23AM	Loading…
10:23AM	U.S. FDA Approves Ziihera (zanidatamab-hrii) with and without Tislelizumab plus Chemotherapy in First-Line HER2+ Advanced Gastroesophageal Adenocarcinoma (GlobeNewswire)
Aug-24-26 06:48AM	Zymeworks Shares Rise Ahead of Key FDA Decision on Zanidatamab (InvestorsHub)
Aug-11-26 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-06-26 04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
Jul-16-26 06:00AM	Zymeworks to Report Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jul-06-26 11:19AM	A Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting Drugs (PR Newswire)
Jun-30-26 04:35AM	Zymeworks agrees to buy Theravance Biopharma for $929m (Pharmaceutical Business Review) +8.46%
Jun-29-26 08:44AM	Zymeworks To Buy Theravance Biopharma In $929M Deal A Look At What This Deal Means For TBPH Shareholders (Stocktwits)
07:26AM	Why This Biotech Stock Is Falling After a $929 Million Buyout Lifeline (Barrons.com)
06:00AM	Zymeworks to Acquire Theravance Biopharma, Inc. (GlobeNewswire)
04:42AM	Theravance, after clinical setbacks, agrees to $929M buyout (BioPharma Dive)
Jun-18-26 08:00AM	Gandeeva and Zymeworks Use Cryo-EM to Accelerate Antibody Drug Discovery (PR Newswire)
Jun-14-26 06:05PM	Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026 (GlobeNewswire)
May-14-26 04:05PM	Zymeworks Announces Share Repurchase Program of up to $125 Million of its Common Stock (GlobeNewswire)
May-13-26 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
04:05PM	Loading…
May-07-26 04:05PM	Zymeworks Provides Corporate Update and Reports First Quarter 2026 Financial Results (GlobeNewswire) -10.19%
Apr-21-26 05:30PM	Zymeworks Presents New Phase 1 Data for ZW191, a Folate Receptor Alpha-Targeting ADC at AACR Annual Meeting 2026 (GlobeNewswire)
Apr-17-26 03:00PM	Zymeworks Presents New Preclinical Data at AACR 2026 Highlighting Broad Antibody-Drug Conjugate Programs Including Novel RAS-Targeting Platform (GlobeNewswire)
Apr-16-26 06:00AM	Zymeworks to Report First Quarter 2026 Financial Results and Host Conference Call on May 7, 2026 (GlobeNewswire)
Apr-09-26 06:00AM	Zymeworks Announces Additional Leadership Appointments to Advance Next Phase of Growth (GlobeNewswire)
Apr-01-26 06:00AM	Zymeworks Appoints Kristin Stafford as Chief Financial Officer (GlobeNewswire)
Mar-30-26 06:00AM	Zymeworks Receives U.S. FDA Fast Track Designation for ZW191, an FRa-Targeting Antibody-Drug Conjugate (GlobeNewswire)
Mar-24-26 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Mar-18-26 07:46AM	Zymeworks Announces Presentations for Ziihera (zanidatamab-hrii) at 2026 AACR Annual Meeting (GlobeNewswire)
Mar-17-26 05:02PM	Zymeworks to Present Clinical and Preclinical Data on ADC Programs Including Novel RAS ADC Platform at AACR Annual Meeting (GlobeNewswire)
Mar-02-26 04:01PM	Zymeworks Inc (ZYME) Q4 2025 Earnings Call Highlights: Strategic Milestones and Financial Resilience (GuruFocus.com)
10:37AM	Zymeworks Q4 Earnings Call Highlights (MarketBeat)
07:15AM	Zymeworks Inc. (ZYME) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
06:01AM	Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing (GlobeNewswire)
06:00AM	Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Feb-25-26 12:15PM	Alkermes (ALKS) Q4 Earnings and Revenues Top Estimates (Zacks)
Feb-12-26 06:00AM	Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026 (GlobeNewswire)
Jan-27-26 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Jan-12-26 06:00AM	Zymeworks Announces Leadership Appointments and Transitions to Align with Evolution of Corporate Strategy (GlobeNewswire)
Jan-11-26 06:00PM	Zymeworks Outlines Strategic Priorities and Outlook for 2026 (GlobeNewswire)
Jan-09-26 12:19PM	Jazz Pharmaceuticals touts Phase 3 zanidatamab OS win in HER2+ GEA, eyes FDA sBLA in H1 (MarketBeat)
Jan-06-26 01:34PM	Ziihera (zanidatamab-hrii) Combinations Achieve Unprecedented Results in First-Line HER2+ Locally Advanced or Metastatic GEA including more than Two Years Median Overall Survival Benefit (GlobeNewswire) -5.10%
Dec-03-25 09:35AM	Oracle initiated, Uber upgraded: Wall Street's top analyst calls (The Fly)
Dec-02-25 04:05PM	Zymeworks Announces Participation in Upcoming Conferences (GlobeNewswire)
Nov-24-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Nov-18-25 12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
03:38AM	Zymeworks to change course, pursue royalty-driven biotech model (BioPharma Dive)
01:01AM	Zymeworks Appoints Scott Platshon as Acting Chief Investment Officer (GlobeNewswire)
01:00AM	Zymeworks Announces Strategic Initiative to Optimize Value of Licensed Products by Building a Diversified Portfolio of Revenue-Generating Assets (GlobeNewswire)
Nov-17-25 04:13PM	Stocks to Watch Recap: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal) +29.05%
09:35AM	Stocks to Watch Monday: Alphabet, Tesla, Netflix, Zymeworks (The Wall Street Journal)
09:02AM	Jazz, Zymeworks Catapult On Their 'Sweeping Success' In Gastric Cancer (Investor's Business Daily)
08:10AM	Jazz Pharmaceuticals and Zymeworks Report Positive Cancer Treatment Results. The Stocks Soar. (Barrons.com)
06:00AM	Zymeworks Announces Positive HERIZON-GEA-01 Phase 3 Results Supporting Ziihera (zanidatamab-hrii) as HER2-Targeted Agent-of-Choice and New Standard of Care in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GlobeNewswire)
Nov-06-25 05:35PM	Zymeworks Inc. (ZYME) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.04%
04:05PM	Zymeworks Provides Corporate Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 10:00AM	Orchestra BioMed Holdings, Inc. (OBIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-30-25 10:00AM	Zymeworks Inc. (ZYME) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release (Zacks)
Oct-29-25 12:00PM	Zymeworks (ZYME) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Oct-28-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Oct-23-25 12:30PM	Zymeworks Presents Initial Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-? at AACR-NCI-EORTC Conference (GlobeNewswire)
Oct-16-25 09:55AM	Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 25.73%: Here's is How to Trade (Zacks)
06:00AM	Zymeworks to Report Third Quarter 2025 Financial Results and Host Conference Call on November 6, 2025 (GlobeNewswire)
Oct-15-25 09:11AM	Next-Generation Targeted Therapies Reshape Precision Oncology Landscape (PR Newswire)
Oct-14-25 12:00PM	Zymeworks Inc. (ZYME) is a Great Momentum Stock: Should You Buy? (Zacks)
Oct-13-25 04:00PM	Zymeworks to Present Clinical Data from the Phase 1 trial of ZW191, an Antibody-Drug Conjugate Targeting Folate Receptor-?, at AACR-NCI-EORTC International Conference (GlobeNewswire)
Oct-10-25 03:20PM	Bitcoin Miner Leads Two Health Care Stocks To New Highs (Investor's Business Daily) +6.74%
09:36AM	Align downgraded, NetEase upgraded: Wall Street's top analyst calls (The Fly)
Oct-09-25 08:30AM	InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors (Newsfile)
06:00AM	Zymeworks Appoints Dr. Adam Schayowitz as Acting Chief Development Officer (GlobeNewswire)
Sep-02-25 12:30PM	Zymeworks Pulls Plug On Early-Stage Cancer Potential As Therapy Unlikely To Provide Benefit (Benzinga) -5.40%
06:00AM	Zymeworks Announces Decision to Discontinue Clinical Development of ZW171, a Mesothelin-directed T cell Engager (GlobeNewswire)
Aug-19-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
Aug-14-25 11:41AM	Kodiak Q2 Loss Wider Than Expected, Pipeline Development in Focus (Zacks)
Aug-12-25 10:26AM	Immunovant's Q1 Loss Narrower Than Expected, Pipeline in Focus (Zacks)
09:55AM	Zymeworks (ZYME) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-11-25 06:00AM	Zymeworks Strengthens Board of Directors with Appointments of Greg Ciongoli and Robert E. Landry (GlobeNewswire)
Aug-07-25 06:35PM	Zymeworks Inc. (ZYME) Tops Q2 Earnings and Revenue Estimates (Zacks)
04:05PM	Zymeworks Provides Corporate Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Jul-29-25 11:03AM	Bispecific Antibodies Market Report 2025- 2035, with Profiles of Akeso Biopharma, Alexion, Amgen, Genmab, Immunocore, Linton Pharm, Merck, OncXerna Therapeutics, Zymeworks, and More (GlobeNewswire)
Jul-28-25 06:00AM	Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW251, a Novel Glypican 3-Targeted Topoisomerase 1 Inhibitor Antibody-Drug Conjugate (GlobeNewswire)
Jul-18-25 09:58AM	Zymeworks (ZYME) Surges 7.1%: Is This an Indication of Further Gains? (Zacks)
Jul-17-25 06:00AM	Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025 (GlobeNewswire) +7.10%
Jul-10-25 12:00PM	Life Sciences BC Announces 2025 Awards Winners, Honouring Excellence in Health Innovation (Business Wire)
Jun-20-25 12:00PM	All You Need to Know About Zymeworks (ZYME) Rating Upgrade to Buy (Zacks)
Jun-04-25 09:55AM	Wall Street Analysts See a 76.74% Upside in Zymeworks (ZYME): Can the Stock Really Move This High? (Zacks)
May-30-25 06:00AM	Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer (GlobeNewswire)
May-22-25 05:00PM	Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences (GlobeNewswire)
May-21-25 06:00AM	Zymeworks Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-19-25 04:15PM	Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference (GlobeNewswire) +5.16%

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Schayowitz Adam	EVP, Head of R&D	Oct 09 '26	Option Exercise	0.00	37,037	0	37,037	Oct 09 06:28 PM
Schayowitz Adam	EVP, Head of R&D	Oct 09 '26	Sale	25.85	13,832	357,557	23,205	Oct 09 06:28 PM
Adam Schayowitz	officer	Oct 09 '26	Proposed Sale	25.26	13,832	349,396		Oct 09 11:16 AM
Jeffrey T L Smith	Former Officer	Mar 06 '26	Proposed Sale	24.80	247,333	6,133,858		Mar 06 09:00 PM
Leone D Patterson	Former officer	Feb 17 '26	Proposed Sale	22.60	31,641	715,087		Feb 17 09:00 PM
Leone D Patterson	Former officer	Feb 13 '26	Proposed Sale	23.17	128,548	2,978,457		Feb 13 09:00 PM
Hollywood Mark	EVP & Chief Operating Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	139,033	Jan 13 05:11 PM
Hollywood Mark	EVP & Chief Operating Officer	Jan 12 '26	Sale	22.67	6,120	138,762	132,913	Jan 13 05:11 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	36,018	Jan 12 09:00 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 12 '26	Sale	22.67	9,310	211,090	26,708	Jan 12 09:00 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 12 '26	Option Exercise	0.00	17,666	0	58,057	Jan 12 08:32 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 12 '26	Sale	22.67	9,560	216,759	48,497	Jan 12 08:32 PM
Galbraith Kenneth	Chair & CEO	Jan 12 '26	Option Exercise	0.00	64,000	0	257,266	Jan 12 07:07 PM
Galbraith Kenneth	Chair & CEO	Jan 12 '26	Sale	22.67	30,424	689,819	226,842	Jan 12 07:07 PM
Leone D Patterson	Former officer	Jan 12 '26	Proposed Sale	23.17	6,832	158,297		Jan 12 05:00 PM
Kenneth Galbraith	Officer	Jan 12 '26	Proposed Sale	23.17	30,424	704,924		Jan 12 05:00 PM
Paul Andrew Moore	Officer	Jan 12 '26	Proposed Sale	23.17	9,560	221,505		Jan 12 05:00 PM
Jeffrey T L Smith	Officer	Jan 12 '26	Proposed Sale	23.17	9,310	215,713		Jan 12 05:00 PM
Mark Hollywood	Officer	Jan 12 '26	Proposed Sale	23.17	6,120	141,800		Jan 12 05:00 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 05 '26	Option Exercise	0.00	20,000	0	28,890	Jan 05 08:22 PM
Smith Jeffrey T L	EVP & Chief Medical Officer	Jan 05 '26	Sale	25.10	10,538	264,471	18,352	Jan 05 08:22 PM
Galbraith Kenneth	Chair & CEO	Jan 05 '26	Option Exercise	0.00	114,334	0	224,952	Jan 05 08:20 PM
Galbraith Kenneth	Chair & CEO	Jan 05 '26	Sale	25.10	54,343	1,363,841	158,286	Jan 05 08:20 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '26	Option Exercise	0.00	37,168	0	51,212	Jan 05 08:18 PM
Moore Paul Andrew	Chief Scientific Officer	Jan 05 '26	Sale	25.10	20,110	504,699	31,212	Jan 05 08:18 PM
Smith Jeffrey T L	Officer	Jan 05 '26	Proposed Sale	26.62	10,538	280,522		Jan 05 07:00 PM
Kenneth Galbraith	Officer	Jan 05 '26	Proposed Sale	26.62	54,343	1,446,611		Jan 05 07:00 PM
Paul Andrew Moore	Officer	Jan 05 '26	Proposed Sale	26.62	20,110	535,328		Jan 05 07:00 PM
Galbraith Kenneth	Chair & CEO	Dec 22 '25	Option Exercise	0.00	100,000	0	180,803	Dec 22 05:52 PM
Galbraith Kenneth	Chair & CEO	Dec 22 '25	Sale	27.02	47,528	1,284,311	133,275	Dec 22 05:52 PM
Galbraith, Kenneth	Officer	Dec 22 '25	Proposed Sale	27.23	47,528	1,294,187		Dec 22 05:00 PM
Derek John Michael Miller	Former Director	Nov 24 '25	Proposed Sale	23.82	118,000	2,810,760		Nov 24 08:00 PM
Neil Gallagher	Former Director	Nov 21 '25	Proposed Sale	23.82	105,000	2,501,100		Nov 21 08:00 PM

Zymeworks, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Its product includes Zanidatamab, which is a novel bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Zanidatamab's unique binding properties result in multiple mechanisms of action that may enable it to address unmet need in patient populations with HER2-expressing cancers. The company was founded on September 8, 2003 and is headquartered in Middletown, DE.

Chairman of the BoardMr. Kenneth H. Galbraith C.A.

Chief Scientific OfficerDr. Paul A. Moore Ph.D.

Executive VP & Chief Business OfficerMr. Scott Platshon B.S.

Executive VP & CFOMs. Kristin Stafford C.P.A.

Executive VP & COOMr. Mark Hollywood

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ZYME

Zymeworks BC Inc

Upgrade your Finviz experience

All the Features.
Half the Price.